The C3d-fused Porcine circovirus type 2d virus-like particle induced early and enhanced immune response and protected pigs against challenge

IF 2.4 2区农林科学 Q3 MICROBIOLOGY

Veterinary microbiology Pub Date : 2024-11-12 DOI:10.1016/j.vetmic.2024.110305

Xinyu Qi , Zheng Fang , Liang Meng , Xuyan Xiang , Yan Ju , Xuehui Cai , Tongqing An , Mingxia Sun , Haiwei Wang

{"title":"The C3d-fused Porcine circovirus type 2d virus-like particle induced early and enhanced immune response and protected pigs against challenge","authors":"Xinyu Qi , Zheng Fang , Liang Meng , Xuyan Xiang , Yan Ju , Xuehui Cai , Tongqing An , Mingxia Sun , Haiwei Wang","doi":"10.1016/j.vetmic.2024.110305","DOIUrl":null,"url":null,"abstract":"<div><div>Porcine circovirus type 2 (PCV2) is an economically significant pathogen affecting the global swine industry. Vaccination is considered the most effective and best way to prevent PCV2-associated disease. The PCV2d genotype has become predominant by replacing the previous PCV2b genotype. The potential increase in the virulence of PCV2d has drawn attention, spurring the development of PCV2d vaccines. Virus-like particle (VLP) is an ideal vaccine candidate for its safety and potent immunogenicity. C3d is a molecular adjuvant that can be used to promote the protective efficacy of the PCV2 vaccine. In this study, we expressed PCV2d Cap protein fused with C3d epitope using <em>E. coli</em> expression system. The purified recombinant Cap protein assembled into VLP, which was designated as PCV2d-C3d-VLP. Through assessments in mice and piglets, we demonstrated that the PCV2d-C3d-VLP elicited robust humoral responses, notably accelerating antibody production one week earlier compared to a commercial PCV2d subunit vaccine. Furthermore, vaccination substantially reduced PCV2d viral load in piglets. These results present an innovative strategy for developing a more efficacious and cost-effective PCV2d VLP vaccine.</div></div>","PeriodicalId":23551,"journal":{"name":"Veterinary microbiology","volume":"299 ","pages":"Article 110305"},"PeriodicalIF":2.4000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary microbiology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378113524003274","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Porcine circovirus type 2 (PCV2) is an economically significant pathogen affecting the global swine industry. Vaccination is considered the most effective and best way to prevent PCV2-associated disease. The PCV2d genotype has become predominant by replacing the previous PCV2b genotype. The potential increase in the virulence of PCV2d has drawn attention, spurring the development of PCV2d vaccines. Virus-like particle (VLP) is an ideal vaccine candidate for its safety and potent immunogenicity. C3d is a molecular adjuvant that can be used to promote the protective efficacy of the PCV2 vaccine. In this study, we expressed PCV2d Cap protein fused with C3d epitope using E. coli expression system. The purified recombinant Cap protein assembled into VLP, which was designated as PCV2d-C3d-VLP. Through assessments in mice and piglets, we demonstrated that the PCV2d-C3d-VLP elicited robust humoral responses, notably accelerating antibody production one week earlier compared to a commercial PCV2d subunit vaccine. Furthermore, vaccination substantially reduced PCV2d viral load in piglets. These results present an innovative strategy for developing a more efficacious and cost-effective PCV2d VLP vaccine.

查看原文本刊更多论文

融合 C3d 的猪圆环病毒 2d 型病毒样颗粒可诱导早期和增强免疫反应，保护猪免受挑战。

猪圆环病毒 2 型（PCV2）是影响全球养猪业的一种具有重要经济意义的病原体。接种疫苗被认为是预防 PCV2 相关疾病的最有效和最佳方法。PCV2d 基因型取代了之前的 PCV2b 基因型，成为主要基因型。PCV2d 毒力的潜在增强引起了人们的关注，从而推动了 PCV2d 疫苗的开发。病毒样颗粒 (VLP) 因其安全性和强大的免疫原性而成为理想的候选疫苗。C3d 是一种分子佐剂，可用于提高 PCV2 疫苗的保护效力。在本研究中，我们利用大肠杆菌表达系统表达了与 C3d 表位融合的 PCV2d Cap 蛋白。纯化后的重组 Cap 蛋白组装成 VLP，命名为 PCV2d-C3d-VLP。通过对小鼠和仔猪的评估，我们证明 PCV2d-C3d-VLP 能引起强大的体液反应，与商用 PCV2d 亚单位疫苗相比，它能显著提前一周加速抗体的产生。此外，接种疫苗还大大降低了仔猪体内的 PCV2d 病毒载量。这些结果为开发更有效、更经济的 PCV2d VLP 疫苗提供了一种创新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Veterinary microbiology 农林科学-兽医学

CiteScore

5.90

自引率

6.10%

发文量

221

审稿时长

52 days

期刊介绍： Veterinary Microbiology is concerned with microbial (bacterial, fungal, viral) diseases of domesticated vertebrate animals (livestock, companion animals, fur-bearing animals, game, poultry, fish) that supply food, other useful products or companionship. In addition, Microbial diseases of wild animals living in captivity, or as members of the feral fauna will also be considered if the infections are of interest because of their interrelation with humans (zoonoses) and/or domestic animals. Studies of antimicrobial resistance are also included, provided that the results represent a substantial advance in knowledge. Authors are strongly encouraged to read - prior to submission - the Editorials (''Scope or cope'' and ''Scope or cope II'') published previously in the journal. The Editors reserve the right to suggest submission to another journal for those papers which they feel would be more appropriate for consideration by that journal. Original research papers of high quality and novelty on aspects of control, host response, molecular biology, pathogenesis, prevention, and treatment of microbial diseases of animals are published. Papers dealing primarily with immunology, epidemiology, molecular biology and antiviral or microbial agents will only be considered if they demonstrate a clear impact on a disease. Papers focusing solely on diagnostic techniques (such as another PCR protocol or ELISA) will not be published - focus should be on a microorganism and not on a particular technique. Papers only reporting microbial sequences, transcriptomics data, or proteomics data will not be considered unless the results represent a substantial advance in knowledge. Drug trial papers will be considered if they have general application or significance. Papers on the identification of microorganisms will also be considered, but detailed taxonomic studies do not fall within the scope of the journal. Case reports will not be published, unless they have general application or contain novel aspects. Papers of geographically limited interest, which repeat what had been established elsewhere will not be considered. The readership of the journal is global.